Search results
Is Most-Watched Stock Meta Platforms, Inc. (FB) Worth Betting on Now?
Zacks via Yahoo Finance· 2 years agoMeta Platforms (FB) has received quite a bit of attention from Zacks.com users lately. Therefore, it...
FB Financial Insiders Placed Bullish Bets Worth US$4.59m
Simply Wall St. via Yahoo Finance· 4 months agoIn the last year, multiple insiders have substantially increased their holdings of FB Financial...
FB Financial (FBK) Misses Q2 Earnings and Revenue Estimates
Zacks via Yahoo Finance· 2 years agoFB Financial (FBK) delivered earnings and revenue surprises of -17.95% and 4.35%, respectively, for...
FB Financial Corporation (NYSE:FBK) Goes Ex-Dividend Soon
Simply Wall St. via Yahoo Finance· 1 month agoSome investors rely on dividends for growing their wealth, and if you're one of those dividend...
James Ayers Adds To FB Financial Holding
Simply Wall St. via Yahoo Finance· 10 months agoThose following along with FB Financial Corporation (NYSE:FBK) will no doubt be intrigued by the recent purchase of shares by insider James Ayers, who...
Analysts Estimate FB Financial (FBK) to Report a Decline in Earnings: What to Look Out for
Zacks via Yahoo Finance· 2 years agoFB Financial (FBK) doesn't possess the right combination of the two key ingredients for a likely...
Should You Buy FB Financial Corporation (NYSE:FBK) For Its Upcoming Dividend?
Simply Wall St. via Yahoo Finance· 1 year agoSome investors rely on dividends for growing their wealth, and if you're one of those dividend...
Avnet and Zumiez have been highlighted as Zacks Bull and Bear of the Day
Zacks via Yahoo Finance· 2 years agoFor Immediate Release Chicago, IL – June 9, 2022 – Zacks Equity Research shares Avnet AVT as the...
If EPS Growth Is Important To You, FB Financial (NYSE:FBK) Presents An Opportunity
Simply Wall St. via Yahoo Finance· 2 years agoThe excitement of investing in a company that can reverse its fortunes is a big draw for some...
Ionis (IONS) Partner to Begin Phase III Study on Kidney Drug
Zacks via Yahoo Finance· 2 years agoIonis (IONS) states that its partner Roche will advance IONIS-FB-L Rx into a phase III study for the...